| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/1996 | DE19500662A1 Estradiolhaltiges Pflaster Estradiolhaltiges paving |
| 07/18/1996 | CA2735293A1 Nadh and nadph therapeutic agents for dermal administration |
| 07/18/1996 | CA2210811A1 Dietary phytoestrogen in estrogen replacement therapy |
| 07/18/1996 | CA2210390A1 Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products |
| 07/18/1996 | CA2210341A1 Transdermal therapeutic system for dispensing (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts |
| 07/18/1996 | CA2210322A1 Novel compounds |
| 07/18/1996 | CA2210233A1 Treatment of movement disorders using large neutral amino acids |
| 07/18/1996 | CA2209938A1 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 07/18/1996 | CA2209936A1 Indole derivatives useful in the treatment of osteoporosis |
| 07/18/1996 | CA2209895A1 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
| 07/18/1996 | CA2209891A1 Methods of inhibiting growth hormone effects |
| 07/18/1996 | CA2209555A1 Tnf-.alpha. inhibitor |
| 07/18/1996 | CA2209496A1 Novel peptides, their production and use |
| 07/18/1996 | CA2209492A1 Compositions for the delivery of antigens |
| 07/18/1996 | CA2209125A1 Compounds for and method of inhibiting phosphodiesterase iv |
| 07/18/1996 | CA2208868A1 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia |
| 07/18/1996 | CA2208861A1 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders |
| 07/18/1996 | CA2208859A1 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment |
| 07/18/1996 | CA2208571A1 Resin particle, medical material and pharmaceutical preparation containing said resin particle |
| 07/18/1996 | CA2208019A1 Antifungal fusacandins |
| 07/18/1996 | CA2207252A1 Inhibitors of prenyl transferases |
| 07/18/1996 | CA2185246A1 Pharmaceutical composition of indene derivatives for regulating apoptosis |
| 07/18/1996 | CA2167254A1 Controlled release of steroids from sugar coatings |
| 07/18/1996 | CA2167104A1 Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
| 07/17/1996 | EP0721955A2 Diadenosine tetraphosphate tetrasodium salt dodecahydrate crystals |
| 07/17/1996 | EP0721950A2 Cardioactive 3-alkoxycarbonyl-thiadiazinones |
| 07/17/1996 | EP0721948A1 Quinolone- and naphthyridone carboxylic acid derivatives as antibacterial agents |
| 07/17/1996 | EP0721947A1 Alkyl(hetero)cyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/17/1996 | EP0721941A1 Novel compound having platelet aggregation inhibitor effect |
| 07/17/1996 | EP0721939A1 N-arylalkylphenylacetamide derivatives |
| 07/17/1996 | EP0721938A1 Alkyl(hetero)cyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/17/1996 | EP0721785A2 Delittered ranitidin preparation |
| 07/17/1996 | EP0721779A2 Combination of active agents, against superinfections, containing a mixture of wool wax acids and alpha-omega alkanoic dicarboxylic acids |
| 07/17/1996 | EP0721778A2 NK-1 receptor antagonists for the treatment of neuronal injury and stroke |
| 07/17/1996 | EP0721777A2 Use of tomoxetine for the treatment of attention deficit/hyperactivity disorder |
| 07/17/1996 | EP0721775A2 Combination of active agents efficcient against unhealthy skin, mild acne and grampositive bacteria |
| 07/17/1996 | EP0721742A1 Nutrition for elderly patients |
| 07/17/1996 | EP0721503A1 USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE $g(b)/A4 AMYLOID-INDUCED MORPHOLOGY |
| 07/17/1996 | EP0721501A1 Pharmaceutical composition comprising phosphatase or a derivative thereof |
| 07/17/1996 | EP0721469A1 Anti-gp39 antibodies and uses therefor |
| 07/17/1996 | EP0721462A1 4-azasteroids with side-chain fluoroketones |
| 07/17/1996 | EP0721460A1 3-carboxysteroids with a fluorinated side chain |
| 07/17/1996 | EP0721459A1 Novel oligosaccharide-containing 14-aminosteroid compounds and novel diastereoselective aminosteroid process chemistry |
| 07/17/1996 | EP0721457A1 2',5'-OLIGOADENYLATE-2',3'-CYCLOPHOSPHATES and 2',5'-OLIGOADENYLATES with antipapilloma virus activity |
| 07/17/1996 | EP0721456A1 Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them |
| 07/17/1996 | EP0721455A1 Tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors |
| 07/17/1996 | EP0721454A1 New pyrazole derivatives as angiotensin ii antagonist |
| 07/17/1996 | EP0721449A1 INHIBITORS OF $g(b)-AMYLOID PROTEIN PRODUCTION |
| 07/17/1996 | EP0721447A1 Anthracene derivatives for use as anticancer agent or dye |
| 07/17/1996 | EP0721350A1 Intracellular immunization |
| 07/17/1996 | EP0721349A1 Monoglyceride/lactate ester permeation enhancer for oxybutynin |
| 07/17/1996 | EP0721348A1 Monoglyceride/lactate ester permeation enhancer |
| 07/17/1996 | EP0721347A1 Agent against sensitive, hyperreactive and hypoactive states of the skin, forms of acne, atopic dermatitides, psoriasis, prurigo, photodermatoses, ichthyosis and viral infections |
| 07/17/1996 | EP0721346A1 Methods for inducing antigen-specific t cell tolerance |
| 07/17/1996 | EP0721338A1 Ranitidine and calcium carbonate pharmaceutical combination product |
| 07/17/1996 | EP0721337A1 Oral formulations of an antifungal |
| 07/17/1996 | EP0721336A1 Benzazole compounds for use in therapy |
| 07/17/1996 | EP0721335A1 Mycophenolate mofetil high dose oral suspensions |
| 07/17/1996 | EP0721334A1 Transdermal therapeutic system containing octyl dodecanol as crystallization inhibitor |
| 07/17/1996 | EP0721330A1 Pharmaceutical composition |
| 07/17/1996 | EP0721329A1 Process for preparation of solid disperions and deposits as well as of solid medicinal forms with dihydropyridine type calcium antagonists |
| 07/17/1996 | EP0721328A1 Camptothecin formulations |
| 07/17/1996 | EP0721324A1 Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use |
| 07/17/1996 | EP0721300A1 Substantive antimicrobial phosphates |
| 07/17/1996 | EP0711301A4 Processes and intermediates for phosphorous-containing covalent linkages |
| 07/17/1996 | EP0638121B1 Targeted cleavage of rna using eukaryotic ribonuclease p and external guide sequence |
| 07/17/1996 | EP0609289B1 Imidazole derivatives and pharmaceutical compositions containing the same |
| 07/17/1996 | EP0601088B1 Use of n-acetyl-l-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| 07/17/1996 | EP0549704B1 Complexes of nitric oxide with polyamines |
| 07/17/1996 | CN2231102Y Lapping agent type anthelmintic salt brick for animals |
| 07/17/1996 | CN1126997A Novel erythromycin derivatives, method for preparing same and use thereof as drugs |
| 07/17/1996 | CN1126996A ABEO-ergoline derivatives as 5HT1A ligands |
| 07/17/1996 | CN1126995A Antiallergic imidazoazepines |
| 07/17/1996 | CN1126994A Novel (1-heteroazolyl-1-heterocyclyl) alkane derivatives and their use as neuroprotective agents |
| 07/17/1996 | CN1126993A Magnesium omeprazole |
| 07/17/1996 | CN1126991A Novel (1-phenyl-1-heterocyclyl) methanol and (1-phenyl-1-heterocyclyl) methylamine derivatives |
| 07/17/1996 | CN1126990A Novel (1-phenyl-1-heterocyclyl) alkane derivatives and their use as neuroprotective agents |
| 07/17/1996 | CN1126988A Difluoro statone analogs |
| 07/17/1996 | CN1126947A Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis |
| 07/17/1996 | CN1126946A New pharmaceutical formulation |
| 07/17/1996 | CN1126727A 11,21-bisphenyl-19-norpregnane derivatives |
| 07/17/1996 | CN1126726A Process for N-acyl-5-fluorocytidine derivatives |
| 07/17/1996 | CN1126723A Preparation of derivative of 4-deoxcide-4-surface-podocyllin poison |
| 07/17/1996 | CN1126720A Heterocyclo-benzoylguanidin |
| 07/17/1996 | CN1126592A Baifuping cream for dermatosis |
| 07/17/1996 | CN1126591A Agent for treating hepato biliary diseases |
| 07/17/1996 | CN1126590A Pharmaceutical compositions and a process for the preparation thereof |
| 07/17/1996 | CN1032309C 吲哚衍生物 Indole derivatives |
| 07/17/1996 | CN1032308C Process for preparing optically active 2-oxoimidazolidine derivatives |
| 07/17/1996 | CN1032292C Method for preparing water-soluble antibiotic composition and water-soluble salts of new cephem compounds |
| 07/16/1996 | US5536850 Substance DC114-A1 |
| 07/16/1996 | US5536848 Bioactive acetogenins and derivatives |
| 07/16/1996 | US5536847 Antitumor agents |
| 07/16/1996 | US5536836 Process for the preparation of 2-(4-[4-(4-chloro-1-pyrazolyl)butyl]-1-piperazinyl)pyrimidine (Lesopitron) |
| 07/16/1996 | US5536832 N-acyl-2,3-benzodiazepine derivatives pharmaceutical compositions containing them and process for preparing same |
| 07/16/1996 | US5536828 (E)-20 (22)-dehydrodiels-alder compounds |
| 07/16/1996 | US5536753 Stable perfluorocarbon and oil emulsions |
| 07/16/1996 | US5536752 Phenyl heterocycles as COX-2 inhibitors |
| 07/16/1996 | US5536751 Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
| 07/16/1996 | US5536749 Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents |